Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1b/2, Multicenter Open-label Study of the Safety and Activity of Carfilzomib in Subjects With Relapsed Solid Tumors, Multiple Myeloma or Lymphoma

NCT00531284 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT00531284
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00531284 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1b/2, Multicenter Open-label Study of the Safety and Activity of Carfilzomib in Subjects With Relapsed Solid Tumors, Multiple Myeloma or Lymphoma
Lead sponsor
Amgen
Phase
Phase 1/2
Overall status
Completed
Start date
September 30, 2007
Completion date
May 22, 2017
Enrollment
184 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoma, multiple myeloma, non-small cell lung cancer, ovarian cancer, renal cancer, small cell lung cancer, solid tumors